Amyloid imaging for dementia in clinical practice

BMC Medicine

Karl Herholz²  John T. O’Brien¹ 

[1] Department of Psychiatry, University of Cambridge, Box 189, Level E4 Cambridge Biomedical Campus, Cambridge CB2 0SP, UK;The University of Manchester, Institute of Brain, Behaviour and Mental Health, Wolfson Molecular Imaging Centre, 27 Palatine Road, Manchester M20 3LJ, UK

关键词: Positron emission tomography;    Imaging;    Dementia;    Amyloid;   

Others  :  1219814
DOI  :  10.1186/s12916-015-0404-6

 received in 2015-05-05, accepted in 2015-06-19,  发布年份 2015

【 摘 要 】

In vivo imaging of brain amyloid using positron emission tomography (PET) scanning is widely used in research studies of dementia, with three amyloid PET ligands being licenced for clinical use. The main clinical use of PET is to help confirm or exclude the likely diagnosis of Alzheimer’s disease in challenging cases, where diagnostic uncertainty remains after current clinical and investigative work up. Whilst diagnostically valuable in such select cases, much wider clinical adoption, especially for very early disease, will be limited by both cost and the lack of a currently effective disease-modifying treatment that requires such early case identification. The use of amyloid imaging to appropriately stratify subjects for prognostic studies and therapeutic trials should increase the efficiency and potentially shorten the time of such studies, and its use combined with other biomarkers and genetics will likely lead to new ways of defining and classifying the dementias.

【 授权许可】

   
2015 O'Brien and Herholz.

【 参考文献 】

• [1]Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol. 2011; 10:667-70.
• [2]Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al.. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012; 11:669-78.
• [3]Leinonen V, Rinne JO, Wong DF, Wolk DA, Trojanowski JQ, Sherwin PF et al.. Diagnostic effectiveness of quantitative [ 18 F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta Neuropathol Commun. 2014; 2:46. BioMed Central Full Text
• [4]Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid plaques in Alzheimer disease: Phase 3 study. Alzheimers Dement. 2015. Ahead of print.
• [5]Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M et al.. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014; 41:1398-407.
• [6]Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al.. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013; 12:357-67.
• [7]Jack CR, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P et al.. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013; 81:1732-40.
• [8]Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ et al.. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015; 11:1-15.
• [9]Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O et al.. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012; 33:416-22.
• [10]Alzheimer’s Disease International. National Alzheimer and Dementia Plans Planned Policies and Activities. Early Detection, Access to Diagnosis, and Stigma Reduction; 2012. http://www. alz.co.uk/sites/default/files/national-alzheimer-and-dementia-plans.pdf webcite
• [11]Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P et al.. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013; 9:e–1–16.
• [12]Jack CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM et al.. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. Lancet Neurol. 2014; 13:997-1005.
• [13]Kobylecki C, Langheinrich T, Hinz R, Vardy ERLC, Brown G, Martino M-E et al.. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. J Nucl Med. 2015; 56:386-91.
• [14]Donaghy P, Thomas AJ, O’Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry. 2015; 23:23-37.
• [15]O’Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K et al.. Is isoflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open. 2014; 4:e005122.
• [16]Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P et al.. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010; 9:1118-27.
• [17]McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al.. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:263-9.
• [18]Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015; 14:114-24.
• [19]Patricio CM, Gabriela C, Julieta RM, Marcos FS, Federico N, Griselda R, et al. Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic. Am J Alzheimers Dis Other Demen. 2015. Ahead of print.
• [20]Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al.. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014; 370:322-33.